Samuel Marynick
Endocrinology, Diabetes & Metabolism · Dallas, TXNPI 1801854187
Payments from drug & device makers
Across 64 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals Inc.$293
- Novo Nordisk$212
- Ascendis Pharma Endocrinology Inc$110
- Amryt Pharma Holdings Ltd$107
- Coopersurgical, Inc.$87
- Alvogen Inc$71
- plus $391 from 16 others
What the payments were for
- Food & beverage$1,25298%
- Education$202%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals Inc. | 23 | $293 |
| Novo Nordisk | 1 | $212 |
| Ascendis Pharma Endocrinology Inc | 6 | $110 |
| Amryt Pharma Holdings Ltd | 5 | $107 |
| Coopersurgical, Inc. | 1 | $87 |
| Alvogen Inc | 4 | $71 |
| Amarin Pharma, Inc. | 3 | $58 |
| Amneal Pharmaceuticals LLC | 3 | $55 |
| AbbVie | 3 | $45 |
| Gilead | 1 | $29 |
| Radius Health, Inc. | 1 | $23 |
| Mission Pharmacal Company | 3 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Antares Pharma, Inc. | 1 | $21 |
| Pfizer | 1 | $19 |
| Medtronic | 1 | $16 |
| Bayer | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Amgen | 1 | $12 |
| IBSA Pharma Inc. | 1 | $11 |
| Therapeuticsmd, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Macrilen$212
How this compares
$1,272 in reported general payments places this provider in the 30th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OmnitropeSomatropin | 34 | $62,413 |
| GenotropinSomatropin | 29 | $55,989 |
| Teriparatide | 13 | $30,666 |
| SynthroidLevothyroxine Sodium | 220 | $24,337 |
| MounjaroTirzepatide | 12 | $12,149 |
| Estradiol (Twice Weekly)Estradiol | 46 | $4,480 |
| Liothyronine Sodium | 112 | $4,320 |
| CozaarLosartan Potassium | 13 | $3,796 |
| Testosterone | 18 | $3,241 |
| Armour ThyroidThyroid,pork | 31 | $2,473 |
| HumalogInsulin Lispro | 15 | $2,384 |
| Calcitonin-SalmonCalcitonin,salmon,synthetic | 23 | $2,360 |
| Hydrocortisone | 32 | $1,911 |
| Pravastatin Sodium | 84 | $1,059 |
| Testosterone Cypionate | 15 | $1,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerGenotropin | $19 | $55,98929 claims |
| Alvogen IncTeriparatide | $71 | $30,66613 claims |
| AbbVieSynthroid, Armour Thyroid | $45 | $26,810251 claims |
| Lilly USA, LLCMounjaro, Humalog | $14 | $14,53427 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $55 | $20429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Dallas
- Julio RosenstockDallas$24.9M
- Ildiko LingvayDallas$8.2M
- Peter BresslerDallas$4.2M
- Steve FordanDallas$2.8M
- Pablo MoraDallas$2.1M
- Saleemah FahmiDallas$1.2M
- Priscilla HollanderDallas$1M
- Oksana HamidiDallas$1M
- Amy ShahDallas$953K
- Abhimanyu GargDallas$920K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.